Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


12>>>
39 Items
Title  Creator  Group name  Publishing year 
Prognostic value of the tumor-to-liver density ratio in patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy. A post-hoc study of the STIC-AVASTIN trial Mazard et al. EquipeMY 2024-06-17
Stereotactic MR-Guided Radiotherapy for Liver Metastases: First Results of the Montpellier Prospective Registry Study Bordeau et al. EquipeJPP 2023-02-02
A prospective registry study of stereotactic magnetic resonance guided radiotherapy (MRgRT) for primary liver tumors Bordeau et al. EquipeMY 2023-09-20
[hPG80 and cancer: A new blood biomarker in development for patient monitoring] You et al. EquipeMY 2022-06
Survival after Multimodal Treatment Including Surgery for Metastatic Esophageal Cancer: A Systematic Review Bardol et al. EquipeAT 2022-08-16
Stereotactic MR-Guided Radiotherapy for Pancreatic Tumors: Dosimetric Benefit of Adaptation and First Clinical Results in a Prospective Registry Study Michalet et al. EquipeMY 2022
Stereotactic MR-Guided Adaptive Radiotherapy for Pancreatic Tumors: Updated Results of the Montpellier Prospective Registry Study Bordeau et al. EquipeJPP 2022-12-20
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial Conroy et al. EquipeMY 2022-09-01
Detection of soluble biomarkers of pancreatic cancer in endoscopic ultrasound-guided fine-needle aspiration samples Souche et al. EquipeJC 2022-05
Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial Ychou et al. EquipeMY 2022-05
A prospective, randomized, phase II study to assess the schemas of retreatment with Lutathera® in patients with new progression of an intestinal, well-differentiated neuroendocrine tumor (ReLUTH) Deshayes et al. EquipeJPP 2022-12-22
Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1) Assenat et al. EquipeMY 2021-02-01
Oncological Outcomes after Liver Venous Deprivation for Colorectal Liver Metastases: A Single Center Experience Khayat et al. EquipePM 2021-01-08
Image-Guided Liver Stereotactic Body Radiotherapy Using VMAT and Real-Time Adaptive Tumor Gating: Evaluation of the Efficacy and Toxicity for Hepatocellular Carcinoma Cantaloube et al. EquipeMY 2021-09-28
GOLT1B Activation in Hepatitis C Virus-Infected Hepatocytes Links ER Trafficking and Viral Replication Butterworth et al. EquipePC 2021-12-31
Anticancer Drugs for Intra-Arterial Treatment of Colorectal Cancer Liver Metastases: In-Vitro Screening after Short Exposure Time Fohlen et al. EquipeCG 2021-07-01
Outcome after pancreatectomy for neuroendocrine neoplams according to the WHO 2017 grading system: A retrospective multicentric analysis of 138 consecutive patients Souche et al. EquipeCTCS 2020-06
Deportalization, Venous Congestion, Venous Deprivation: Serial Measurements of Volumes and Functions on Morphofunctional 99mTc-Mebrofenin SPECT-CT Piron et al. EquipePM 2020-12-23
The oncogenic and druggable hPG80 (Progastrin) is overexpressed in multiple cancers and detected in the blood of patients You et al. EquipeMY Dec 23, 2019
Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial Assenat et al. EquipeMY Apr 04, 2019
Quantitative evaluation of liver metastases density on computed tomography: A new tool to evaluate early response to bevacizumab-containing chemotherapy Mazard et al. EquipeMY May 10, 2019
Microvascular invasion is a major prognostic factor after pancreatico-duodenectomy for adenocarcinoma Panaro et al. EquipeAT 2019-09
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer Conroy et al. EquipeMY 12 20, 2018
Autologous cell lines from circulating colon cancer cells captured from sequential liquid biopsies as model to study therapy-driven tumor changes Soler et al. EquipeMY Oct 29, 2018
A prospective clinical and biological database for pancreatic adenocarcinoma: the BACAP cohort Canivet et al. EquipeAD 2018-10-16
12>>>
39 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés